Promoting physiological hypertrophy in the failing heart

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 438-441

  Pretorius, Lynette ^a   Owen, Kate L ^a,b   Jennings, Garry L ^a   McMullen, Julie R ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NONE   (Australia)

Author keywords

Cardiac hypertrophy; Cardioprotection; Exercise; Heart failure; Pathological; Physiological

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C;

CONFERENCE PAPER; CULTURAL ANTHROPOLOGY; EPIDEMIC; EXERCISE; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; NONHUMAN; REGENERATION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

CARDIOMEGALY; EXERCISE; HEART FAILURE; HUMANS;

EID: 40149104252     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04893.x     Document Type: Conference Paper

References (37)

1. AIHW. Heart, stroke and vascular diseases - Australian facts 2004. A report from the Heart Foundation and the Australian Institute of Health and Welfare. Cardiovasc. Dis. Ser. 2004 22 : 1 152.
2. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005 365 : 1877 89.
3. Stewart S, MacIntyre K, Capewell S et al. Heart failure and the aging population: An increasing burden in the 21st century? Heart 2003 89 : 49 53.
4. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 2007 34 : 255 62.
5. Zak R. Growth of the Heart in Health and Disease. Raven Press, New York. 1984 1 24, 131 85, 381 420.
6. Fagard RH. Impact of different sports and training on cardiac structure and function. Cardiol. Clin. 1997 15 : 397 412.
7. Ferrans VJ. Cardiac hypertrophy: Morphological aspects. In : Zak R (ed.). Growth of the Heart in Health and Disease. Raven Press, New York. 1984 187 239.
8. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog. Cardiovasc. Dis. 1974 17 : 5 24.
9. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 1990 322 : 1561 6.
10. Cohn JN, Bristow MR, Chien KR et al. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on heart failure research. Circulation 1997 95 : 766 70.
11. Conlon I, Raff M. Size control in animal development. Cell 1999 96 : 235 44.
12. Neri Serneri GG, Boddi M, Modesti PA et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 2001 89 : 977 82.
13. Koziris LP, Hickson RC, Chatterton RT Jr. et al. Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. J. Appl. Physiol. 1999 86 : 1436 42.
14. Yeh JK, Aloia JF, Chen M et al. Effect of growth hormone administration and treadmill exercise on serum and skeletal IGF-I in rats. Am. J. Physiol. 1994 266 : E129 35.
15. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997 387 : 673 6.
16. Reiss K, Cheng W, Ferber A et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl Acad. Sci. USA 1996 93 : 8630 5.
17. McMullen JR, Shioi T, Huang WY et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110[alpha]) pathway. J. Biol. Chem. 2004 279 : 4782 93.
18. Shioi T, Kang PM, Douglas PS et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000 19 : 2537 48.
19. Luo J, McMullen JR, Sobkiw CL et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 2005 25 : 9491 502.
20. McMullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase (p110[alpha]) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 2003 100 : 12 355 60.
21. Welch S, Plank D, Witt S et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ. Res. 2002 90 : 641 8.
22. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase (p110[alpha]) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 2007 104 : 612 17.
23. Li B, Setoguchi M, Wang X et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ. Res. 1999 84 : 1007 19.
24. Kajstura J, Fiordaliso F, Andreoli AM et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001 50 : 1414 24.
25. Li Q, Li B, Wang X et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J. Clin. Invest. 1997 100 : 1991 9.
26. Coats AJ. Exercise training in heart failure. Curr. Control. Trials Cardiovasc. Med. 2000 1 : 155 60.
27. Konhilas JP, Watson PA, Maass A et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ. Res. 2006 98 : 540 8.
28. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000 101 : 2981 8.
29. Maisch B. Ventricular remodeling. Cardiology 1996 87 (Suppl. 1 2 10.
30. Shiraishi I, Melendez J, Ahn Y et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 2004 94 : 884 91.
31. Le Corvoisier P, Hittinger L, Chanson P et al. Cardiac effects of growth hormone treatment in chronic heart failure: A meta-analysis. J. Clin. Endocrinol. Metab. 2007 92 : 180 5.
32. Barton PJ, Felkin LE, Birks EJ et al. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 2005 112 (9 Suppl I46 50.
33. Colao A, Marzullo P, Di Somma C et al. Growth hormone and the heart. Clin. Endocrinol. (Oxf.) 2001 54 : 137 54.
34. Delaughter MC, Taffet GE, Fiorotto ML et al. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999 13 : 1923 9.
35. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006 9 : 341 9.
36. Foukas LC, Claret M, Pearce W et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006 441 : 366 70.
37. Tarnavski O, McMullen JR, Schinke M et al. Mouse cardiac surgery: Comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genomics 2004 16 : 349 60.